Fifteen percent of African-American men will develop prostate cancer in their lifetime. They’re also more likely to be diagnosed with a more aggressive form of the disease than white men.
To help combat this, NIH is launching one of the largest coordinated studies on aggressive prostate cancer in African-American men.
The $26.5 million study is called RESPOND, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress.
RESPOND investigators aim to enroll 10,000 participants through the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program and the Centers for Disease Control and Prevention’s National Program of Cancer Registries.
NCI and the National Institute on Minority Health and Health Disparities are supporting the research, along with the Prostate Cancer Foundation. The NCI support will be provided from Cancer Moonshot funding authorized in the 21st Century Cures Act.
